Lifesci Capital Has Negative Estimate for VERA Q3 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Research analysts at Lifesci Capital cut their Q3 2025 EPS estimates for Vera Therapeutics in a note issued to investors on Tuesday, August 5th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings per share of ($1.20) for the quarter, down from their previous forecast of ($0.83). The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics’ Q4 2025 earnings at ($1.22) EPS and FY2025 earnings at ($4.44) EPS.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period in the previous year, the firm earned ($0.62) EPS.

A number of other research analysts have also recently weighed in on the stock. Scotiabank reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. JPMorgan Chase & Co. cut their price objective on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price objective (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Wolfe Research reaffirmed a “peer perform” rating on shares of Vera Therapeutics in a report on Monday, August 4th. Finally, Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Vera Therapeutics Trading Up 0.4%

Shares of Vera Therapeutics stock opened at $19.79 on Friday. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 27.68. The firm has a fifty day moving average price of $22.97 and a 200 day moving average price of $25.14. The stock has a market cap of $1.26 billion, a PE ratio of -5.53 and a beta of 1.17.

Insider Activity at Vera Therapeutics

In related news, Director Patrick G. Enright bought 40,607 shares of the business’s stock in a transaction dated Tuesday, June 24th. The stock was acquired at an average price of $22.35 per share, with a total value of $907,566.45. Following the completion of the purchase, the director directly owned 3,596,593 shares of the company’s stock, valued at approximately $80,383,853.55. This trade represents a 1.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 16.30% of the stock is owned by corporate insiders.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System boosted its position in Vera Therapeutics by 19.9% during the fourth quarter. California State Teachers Retirement System now owns 40,640 shares of the company’s stock worth $1,719,000 after acquiring an additional 6,749 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Vera Therapeutics by 31.7% during the fourth quarter. Ameriprise Financial Inc. now owns 30,021 shares of the company’s stock worth $1,270,000 after acquiring an additional 7,227 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Vera Therapeutics by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 143,665 shares of the company’s stock worth $3,451,000 after acquiring an additional 1,717 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Vera Therapeutics during the fourth quarter worth about $264,000. Finally, Rhumbline Advisers boosted its position in Vera Therapeutics by 7.9% during the first quarter. Rhumbline Advisers now owns 63,189 shares of the company’s stock worth $1,518,000 after acquiring an additional 4,600 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.